Zaloguj Zarejestruj się zadarmo

Panbela Therapeutics organizacji Wskaźnik krótkiej sprzedaży

Jaka jest wartość Wskaźnik krótkiej sprzedaży organizacji Panbela Therapeutics?

Wartość Wskaźnik krótkiej sprzedaży organizacji Panbela Therapeutics Inc. to 0.03

Jaka jest definicja Wskaźnik krótkiej sprzedaży?



Wskaźnik krótkiej sprzedaży (Short ratio) to liczba akcji sprzedanych na krótko podzielona przez średnią wartość dzienną.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

Wskaźnik krótkiej sprzedaży firm w Health Care sektor na NASDAQ w porównaniu do Panbela Therapeutics

Czym się zajmuję organizacja Panbela Therapeutics?

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Firmy z wskaźnik krótkiej sprzedaży podobne do Panbela Therapeutics